Tags

Type your tag names separated by a space and hit enter

Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype.
Cancer. 2009 Mar 01; 115(5):936-45.C

Abstract

BACKGROUND

Data from large prospective studies are needed to fully characterize the impact of exogenous hormones on breast cancer incidence by type of hormone preparation and histology of the cancer.

METHODS

In a prospective cohort of 67,754 postmenopausal women in the US, 1821 cases of invasive ductal cancer and 471 cases of invasive lobular or mixed lobular cancer occurred during 13 years of follow-up. The authors computed age-adjusted rates, as well as age-adjusted and multivariate-adjusted rate ratios (RR) for ductal and lobular breast cancer and for the use of estrogen only (E-only) and estrogen and progesterone (E + P) for current and former hormone users by duration of use and years since last use.

RESULTS

Current use of E + P was associated with an increased risk of both ductal (RR of 1.75; 95% confidence interval [95% CI], 1.53-2.01) and lobular (RR of 2.12; 95% CI, 1.62-2.77) breast cancer. Risk increased within the first 2 to 3 years of use and attenuated 2 years after cessation. In contrast, current use of E-only was not associated with an overall increased risk of invasive ductal cancer. The only exceptions to this finding were in lean (body mass index <25) women and for ductal cancers diagnosed at the regional/distant stage, where in both cases the use of E-only was associated with an increased risk. E-only use was associated with a 50% increased risk of invasive lobular cancer after >or=10 years of use.

CONCLUSIONS

Use of E + P is more detrimental to the breast than E-only use, in terms of both ductal and lobular cancer. The findings from the current study suggest a window of 2 to 3 years for the risks of E + P both to become apparent after initial use and to attenuate after cessation.

Authors+Show Affiliations

Department of Epidemiology and Surveillance Research, American Cancer Society, 250 Williams Street, NW, Atlanta, GA 30303, USA. jeanne.calle@cancer.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19156895

Citation

Calle, Eugenia E., et al. "Postmenopausal Hormone Use and Breast Cancer Associations Differ By Hormone Regimen and Histologic Subtype." Cancer, vol. 115, no. 5, 2009, pp. 936-45.
Calle EE, Feigelson HS, Hildebrand JS, et al. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer. 2009;115(5):936-45.
Calle, E. E., Feigelson, H. S., Hildebrand, J. S., Teras, L. R., Thun, M. J., & Rodriguez, C. (2009). Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer, 115(5), 936-45. https://doi.org/10.1002/cncr.24101
Calle EE, et al. Postmenopausal Hormone Use and Breast Cancer Associations Differ By Hormone Regimen and Histologic Subtype. Cancer. 2009 Mar 1;115(5):936-45. PubMed PMID: 19156895.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. AU - Calle,Eugenia E, AU - Feigelson,Heather Spencer, AU - Hildebrand,Janet S, AU - Teras,Lauren R, AU - Thun,Michael J, AU - Rodriguez,Carmen, PY - 2009/1/22/entrez PY - 2009/1/22/pubmed PY - 2009/4/25/medline SP - 936 EP - 45 JF - Cancer JO - Cancer VL - 115 IS - 5 N2 - BACKGROUND: Data from large prospective studies are needed to fully characterize the impact of exogenous hormones on breast cancer incidence by type of hormone preparation and histology of the cancer. METHODS: In a prospective cohort of 67,754 postmenopausal women in the US, 1821 cases of invasive ductal cancer and 471 cases of invasive lobular or mixed lobular cancer occurred during 13 years of follow-up. The authors computed age-adjusted rates, as well as age-adjusted and multivariate-adjusted rate ratios (RR) for ductal and lobular breast cancer and for the use of estrogen only (E-only) and estrogen and progesterone (E + P) for current and former hormone users by duration of use and years since last use. RESULTS: Current use of E + P was associated with an increased risk of both ductal (RR of 1.75; 95% confidence interval [95% CI], 1.53-2.01) and lobular (RR of 2.12; 95% CI, 1.62-2.77) breast cancer. Risk increased within the first 2 to 3 years of use and attenuated 2 years after cessation. In contrast, current use of E-only was not associated with an overall increased risk of invasive ductal cancer. The only exceptions to this finding were in lean (body mass index <25) women and for ductal cancers diagnosed at the regional/distant stage, where in both cases the use of E-only was associated with an increased risk. E-only use was associated with a 50% increased risk of invasive lobular cancer after >or=10 years of use. CONCLUSIONS: Use of E + P is more detrimental to the breast than E-only use, in terms of both ductal and lobular cancer. The findings from the current study suggest a window of 2 to 3 years for the risks of E + P both to become apparent after initial use and to attenuate after cessation. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/19156895/Postmenopausal_hormone_use_and_breast_cancer_associations_differ_by_hormone_regimen_and_histologic_subtype_ L2 - https://doi.org/10.1002/cncr.24101 DB - PRIME DP - Unbound Medicine ER -